Treatment outcome and prognostic factors for patients with bone-only metastases of breast cancer: a single-institution retrospective analysis.
OBJECTIVE
Limited information is available about the optimal management and clinical outcome of bone-only metastases in breast cancer patients. The objective of this study was to define prognostic factors for patients with bone-only metastases. Our second objective was to compare progression-free survival (PFS) and overall survival (OS) between patients with hormone receptor (HR)(+) tumors and bone-only metastases who received combinatory therapy (chemotherapy followed by endocrine therapy, or endocrine therapy combined with molecular targeted therapy) and those treated with endocrine or chemotherapy alone.


METHODS
We retrospectively identified 351 breast cancer patients diagnosed with bone-only metastasis in 1997-2008 at our institution.


RESULTS
Patients with metastasis detected at the time of their primary breast cancer diagnosis (rather than at recurrence), a single metastasis, or asymptomatic bone disease had a longer PFS interval, and patients with a performance status of 0-1, a single metastasis, or asymptomatic bone disease had a longer OS time. Among patients with HR(+) human epidermal growth factor receptor (HER)-2(-) disease, combinatory therapy was associated with longer PFS and OS times than with endocrine therapy. In multivariate analyses, combinatory therapy was not associated with longer PFS or OS times than with endocrine therapy. Among patients with HER-2(+) disease, trastuzumab led to a longer PFS interval but no difference in the OS time.


CONCLUSIONS
Our results indicate that, for HR(+) disease, a prospective trial of chemotherapy followed by endocrine therapy is warranted to determine whether it prolongs survival more than endocrine therapy alone in patients with bone-only metastases.
Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 1354, Houston, Texas 77030, USA.
Naoki
N
Niikura
Jun
J
Liu
Naoki
N
Hayashi
Shana L
SL
Palla
Yutaka
Y
Tokuda
Gabriel N
GN
Hortobagyi
Naoto T
NT
Ueno
Richard L
RL
Theriault
D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000188:drug therapy / Q000401:mortality* / Q000556:secondary*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000401:mortality / Q000473:pathology; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D058990:Molecular Targeted Therapy; D009367:Neoplasm Staging; D011379:Prognosis; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism; D012189:Retrospective Studies; D016019:Survival Analysis; D000068878:Trastuzumab; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab
Surg Gynecol Obstet. 1988 Oct;167(4):303-6
3420504
Surg Clin North Am. 2003 Aug;83(4):803-19
12875597
BMC Cancer. 2009 Aug 06;9:272
19660124
Bone Marrow Transplant. 2006 Jun;37(11):1009-15
16633363
Breast Cancer. 2001;8(4):310-5
11791123
Cancer. 2000 Jul 15;89(2):363-8
10918167
Semin Oncol. 2001 Dec;28(6 Suppl 18):43-7
11774205
Am J Med. 1986 Sep;81(3):381-6
2428242
Cancer Res. 1979 May;39(5):1552-62
427797
Br J Cancer. 1987 Jan;55(1):61-6
3814476
BMC Cancer. 2006 Jul 06;6:179
16824210
J Clin Oncol. 1999 Sep;17(9):2639-48
10561337
Am J Clin Oncol. 1990 Aug;13(4):294-8
2198793
Ann Oncol. 2003 Aug;14(8):1234-40
12881385
N Engl J Med. 1998 Oct 1;339(14):974-84
9753714
Cancer. 1986 Jul 1;58(1):178-82
2423224
Oncology. 2006;71(5-6):374-81
17785994
Br J Cancer. 1998;77(2):336-40
9461007
Cancer. 1986 Dec 15;58(12):2589-93
3779609
Eur J Cancer. 2000 Mar;36(4):476-82
10717523
Clin Breast Cancer. 2009 Aug;9(3):173-7
19661041
J Clin Oncol. 2002 Apr 1;20(7):1800-8
11919237
Surg Gynecol Obstet. 1957 Jul;105(1):97-102
13442910
Neoplasma. 1983;30(1):113-23
6300707
Am J Clin Oncol. 1982 Apr;5(2):161-6
7091041
N Engl J Med. 2001 Mar 15;344(11):783-92
11248153